SNY

Oct 30, 3:30 AMSanofi beats Q3 expectations on business EPS and revenue, raises full-year outlook to low-teens sales and mid-teens EPS growth

Peers: GSK PFE MRK NVO AZN NVS ABBV BMY JNJ LLY

| Held by: AVDE FENI PPH FVD PID GMOI BUSA IDVZ FLV QQQJ

Scroll to Statements

Index	-
Market Cap	106.45B
Enterprise Value	126.55B
Income	4.69B
Sales	53.47B
Book/sh	32.59
Cash/sh	3.05
Dividend Est.	2.39 (5.36%)
Dividend TTM	2.42 (5.42%)
Dividend Ex-Date	May 04, 2026
Dividend Gr. 3/5Y	8.45% 5.14%
Payout	73.36%
Employees	76493
IPO	Jul 01, 2002

P/E	23.00
Forward P/E	8.68
PEG	1.43
P/S	1.99
P/B	1.37
P/C	14.66
P/FCF	8.83
EV/EBITDA	5.63
EV/Sales	2.37
Quick Ratio	0.64
Current Ratio	0.99
Debt/Eq	0.34
LT Debt/Eq	0.24
Option/Short	Yes / Yes

EPS (ttm)	1.94
EPS next Y	5.15
EPS next Q	1.01
EPS this Y	3.85%
EPS next Y	6.11%
EPS next 5Y	6.05%
EPS past 3/5Y	-11.86% -15.52%
Sales past 3/5Y	2.90% 3.69%
EPS Y/Y TTM	-30.90%
Sales Y/Y TTM	23.68%
EPS Q/Q	-32.22%
Sales Q/Q	18.71%
Earnings	Oct 30 BMO
EPS/Sales Surpr.	3.11% 3.35%

Insider Own	0.00%
Insider Trans	-
Inst Own	7.99%
Inst Trans	-0.82%
ROA	3.12%
ROE	5.70%
ROIC	4.80%
Gross Margin	66.29%
Oper. Margin	27.17%
Profit Margin	8.78%
SMA20	8.51%
SMA50	5.87%
SMA200	0.79%
Trades

Shs Outstand	2.43B
Shs Float	2.38B
Short Float	0.49%
Short Ratio	3.79
Short Interest	11.61M
52W High	52.68 -15.22%
52W Low	39.07 14.31%
Volatility	1.70% 1.70%
ATR (14)	0.87
RSI (14)	69.69
Beta	0.28
Rel Volume	0.12
Avg Volume	3.06M
Volume	18,215

Perf Week	6.87%
Perf Month	11.87%
Perf Quarter	4.64%
Perf Half Y	3.02%
Perf YTD	-7.84%
Perf Year	-11.70%
Perf 3Y	-3.98%
Perf 5Y	-13.54%
Perf 10Y	12.95%
Recom	2.10
Target Price	49.80
Prev Close	44.34
Price	44.66
Change %	0.72%

Consensus

Buy

Avg. Price Target

$49.80

Implied Upside

+11.5%

Analysts14incl. previous ratings

Rating Distribution3 Buy · 11 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 09, 2026	Initiated	WWolfe Research	Peer Perform
Sep 09, 2026	Initiated	RRBC Capital Mkts	Sector Perform
May 01, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight
Apr 20, 2026	Downgrade	BBNP Paribas Exane	Outperform → Neutral	$50	+12.0%
Feb 12, 2026	Downgrade	BBofA Securities	Buy → Neutral
Jan 27, 2026	Initiated	CCitigroup	Neutral
Jan 16, 2026	Downgrade	UUBS	Buy → Neutral
Jan 06, 2026	Downgrade	BBarclays	Overweight → Equal Weight
Dec 09, 2025	Downgrade	GGuggenheim	Buy → Neutral
Dec 08, 2025	Downgrade	JJP Morgan	Overweight → Neutral
Sep 08, 2025	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$58	+29.9%
Sep 02, 2025	Upgrade	DDeutsche Bank	Hold → Buy
Aug 08, 2025	Upgrade	JJP Morgan	Neutral → Overweight
Apr 15, 2025	Initiated	EExane BNP Paribas	Outperform	$65	+45.5%
Mar 21, 2025	Initiated	GGoldman	Neutral	$65	+45.5%
Jan 30, 2025	Upgrade	DDeutsche Bank	Sell → Hold
Jul 26, 2024	Reiterated	AArgus	Buy	$55 → $60	+34.3%
Jan 23, 2024	Initiated	MMorgan Stanley	Equal-Weight	$55	+23.2%
Jan 16, 2024	Resumed	UUBS	Buy
Dec 05, 2023	Downgrade	JJP Morgan	Overweight → Neutral

Oct-30-26 08:30AM	REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of Strongest Years Ever After Q3 Earnings Beat (Stocktwits)
07:13AM	Regeneron Q3 revenue tops estimates on Sanofi Dupixent profit; shares rise 4% (Investing.com)
03:22AM	Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance (Investing.com)
Oct-26-26 07:52AM	Novartis Reports Lower Relapse Rates and No Hys Law Cases in Phase 3 Remibrutinib MS Trials (InvestorsHub)
05:32AM	Novartis MS drug remibrutinib cuts relapses, no liver safety signal in trials (Investing.com)
08:29AM	Loading…
Oct-22-26 08:29AM	Sanofi Faces A Proof Test As Vaccine Slump And Dupixent Slowdown Hit Q3 (Earnings Whispers)
Oct-21-26 08:19AM	Sanofi & Tevas IBD drug prompts long-term clinical remission in Phase IIb trial (Clinical Trials Arena)
06:41AM	Sanofi and ScionxBio partner on mRNA therapies (Pharmaceutical Business Review)
Oct-20-26 11:14AM	Investors pledge 230 billion euros at German summit: Merz (AFP)
Oct-15-26 01:59PM	RXRX Stock Heads For Its Best Day In Over A Year Whats Driving The Rally Today? (Stocktwits)
Oct-14-26 05:45PM	What Could Send Regeneron Stock Higher? (Trefis)
Oct-13-26 11:24AM	Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. (Barrons.com)
Oct-12-26 04:59PM	Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up (Investing.com)
Oct-11-26 09:22PM	SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH (Stocktwits)
Oct-08-26 09:00AM	Pharmas $500B patent problem will come in waves not as a cliff (Pharma Voice)
08:13PM	Loading…
Oct-02-26 08:13PM	Stocktwits Biotech Dealmaker Novartis, Sanofi And Novo Sign Weeks Biggest Deals (Stocktwits)
11:57AM	Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID (PR Newswire)
08:26AM	Sanofi pays Regeneron up to $8B to expand immunology alliance (Quartz)
Oct-01-26 11:38AM	Sanofi, Regeneron broaden alliance to find their next Dupixent (BioPharma Dive)
11:03AM	Pfizers eczema drug clears skin in mid-stage trial (BioPharma Dive)
07:40AM	Sanofi and Regeneron expand immunology partnership to the tune of $8bn (Pharmaceutical Technology)
07:36AM	Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights (Stocktwits)
02:00AM	Sanofi gains after expanding Regeneron partnership with $8 billion deal (Investing.com)
Sep-28-26 08:50AM	What Bavarian Nordics next CEO is up against (Pharma Voice)
Sep-23-26 10:52AM	European big pharma unites amid ringing alarm bells of continents dominance (Clinical Trials Arena)
Sep-22-26 03:26PM	AstraZeneca and GSK warn Europes drug industry is at risk (The Telegraph)
Sep-19-26 10:30PM	What does the EU have that the U.S. does not? (Investing.com)
Sep-15-26 06:08AM	Cheplapharm to take over 20 medicines and three sites from Sanofi (Pharmaceutical Business Review)
Sep-10-26 09:05AM	Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID (PR Newswire)
Sep-08-26 08:00AM	Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS (PR Newswire)
06:10AM	Loading…
Sep-04-26 06:10AM	GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says (Proactive)
Sep-02-26 08:33AM	Novartis stock rises after MS drug remibrutinib trial results (Quartz)
Sep-01-26 07:34AM	Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths (Barrons.com)
Aug-28-26 06:34PM	NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open (Stocktwits)
04:22PM	Top Stock Reports for NVIDIA, ExxonMobil & HSBC (Zacks)
Aug-27-26 07:25AM	Pharmas new CEOs to watch (Pharma Voice)
Aug-19-26 06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
Aug-13-26 06:30AM	Big Tech Drives Up Credit Risk for Safe Firms With No AI Links (Bloomberg)
Aug-06-26 07:19PM	Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ... (GuruFocus.com)
05:29PM	NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot Retail Eyes Buyout, More Partnership Deals (Stocktwits)
09:54AM	Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses (InvestorsHub)
Aug-05-26 09:01PM	Euroapi SA (EAPIF) (H1 2026) Earnings Call Highlights: Transformation Costs and Market ... (GuruFocus.com)
01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
Aug-03-26 09:08AM	Medicus Pharma CMO to lead Antev's Teverelix clinical programme (Proactive)
Jul-31-26 07:06AM	Sanofi to rebuild trust with Regeneron; Apnimed adds to string of upsized biotech IPOs (BioPharma Dive)
Jul-30-26 05:04PM	Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ... (GuruFocus.com)
03:03PM	Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ... (GuruFocus.com)
10:00AM	Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results (InvestorsHub)
07:59AM	Regeneron beats quarterly estimates on eczema drug strength, shares rise (Reuters)
05:12AM	How Telix landed a $2.1 billion radiopharma deal with Regeneron (Pharma Voice)
Jul-28-26 05:48AM	Kalshi is expanding online betting in drug R&D unless detractors can stop it (Pharma Voice)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)
11:53AM	Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO (Bloomberg)
10:20AM	Sanofi abandons eczema drug approval efforts in another blow to OX40 class (Pharmaceutical Technology)
08:53AM	Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul (Quartz)
07:35AM	Sanofi halts development of troubled immune drug in eczema (BioPharma Dive)
Jul-20-26 04:00PM	Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase (GuruFocus.com)
Jul-17-26 06:07AM	Arbutus, Sanofi escalate mRNA patent fights; InnoCares TYK2 contender advances (BioPharma Dive)
Jul-16-26 08:00AM	Kalshi Will Offer Sports-Style Betting on Drug Trial Results (Bloomberg)
Jun-30-26 06:53AM	Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger (Pharmaceutical Technology)
Jun-26-26 01:38PM	Sanofi Faces EU Probe With Fines Possibly Reaching 10% (GuruFocus.com)
06:46AM	EU hits France's Sanofi with flu vaccine antitrust probe (AFP)
Jun-25-26 09:00AM	REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan (IPO-Edge.com)
Jun-24-26 04:12AM	Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor (BioPharma Dive)
Jun-23-26 06:21AM	How Kardigan spun deal leftovers into a $400M IPO (BioPharma Dive)
Jun-22-26 02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
07:12AM	Sanofi swaps R&D leaders; Mercks Prometheus deal pays dividends (BioPharma Dive)
05:21AM	Backed by Sanofi and Roche, Orano Med chases radiopharma leadership (Pharma Voice)
05:05AM	Japan approves Sanofi's Sarclisa combo for MM treatment (Pharmaceutical Business Review)
03:00AM	Bionyra brings in $165M for next-generation immune drugs (BioPharma Dive)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis)
Jun-12-26 05:13PM	DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results (Stocktwits)
Jun-11-26 12:21PM	Drug developers eye sports biggest stage as World Cup fever builds (Pharmaceutical Technology)
Jun-10-26 07:28AM	Sanofi stops immune drug trial in latest research setback (BioPharma Dive)
05:48AM	Sanofi Halts Phase 3 CIDP Trial for Riliprubart Following Interim Review (SAN) (InvestorsHub)
Jun-08-26 06:05AM	Sanofi and Owkin partner to develop next-generation biopharma AI agents (Pharmaceutical Business Review)
Jun-01-26 07:17AM	MIT bullish on its Initiative for New Manufacturing at the one-year mark (Manufacturing Dive)
May-29-26 06:06AM	FDA grants priority review for Sanofi's venglustat NDA (Pharmaceutical Business Review)
May-20-26 01:54PM	ATS 2026: Mixed results for Sanofi/Regenerons itepekimab cloud COPD prospects (Clinical Trials Arena)
May-18-26 07:28AM	Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda (Barrons.com)
May-15-26 06:29AM	Sanofis vaccine bump; the new FDA commish (Pharma Voice)
May-06-26 12:42PM	Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 (PR Newswire)
May-05-26 10:14AM	Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE (InvestorsHub)
Apr-30-26 05:24AM	Regeneron Q1 2026 net income falls 10% to $727m (Pharmaceutical Technology)
Apr-29-26 10:12AM	Regeneron shares slide despite Q1 beat (Proactive)
08:53AM	Regeneron Tops Q1 Estimates on Dupixent Momentum (InvestorsHub)
07:15AM	Regeneron beats first quarter estimates on Dupixent strength (Investing.com)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
03:04AM	Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments (GuruFocus.com)
Apr-23-26 07:02AM	Sanofi posts upbeat sales as R&D pressure builds (BioPharma Dive)
06:34AM	Sanofi receives FDA approval for Tzield in paediatric diabetes (Pharmaceutical Business Review)
03:48AM	Sanofi climbs as strong Dupixent sales drive Q1 revenue and profit beat (Investing.com)
Apr-07-26 01:36PM	Sanofis bispecific scores in respiratory diseases but fails in eczema (Clinical Trials Arena)
04:34AM	Sanofi immune drug hopeful posts mixed results in mid-stage tests (BioPharma Dive)
Mar-30-26 05:31AM	Sanofi eczema drug weighed down by mixed results, safety concerns (BioPharma Dive)
Mar-27-26 07:56AM	AstraZeneca lung drug gets surprise win in COPD trials (BioPharma Dive)
Mar-24-26 06:36AM	Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody (Pharmaceutical Business Review)
Mar-23-26 08:15AM	Earendil Labs lands $787m to fund biologics development push (Pharmaceutical Technology)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive)

Show Previous News

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.

CEO & DirectorMs. Belen Garijo Lopez M.D.

Executive VP & CFOMr. Francois-Xavier Roger

Chief Scientific Officer & Head of ResearchDr. Michael Quigley Ph.D.

Head of Investor Relations & General MedicinesMr. Thomas Kudsk Larsen

Executive VP & General CounselMs. Jamie Haney

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Sanofi ADR

Upgrade your Finviz experience